

Recent Advanced Studies on Breast Cancer

Park Yevan Stevens*

Department of Oncology, University of Primorska, Koper, Slovenia

*Corresponding author: Park Yevan Stevens, Department of Oncology, University of Primorska, Koper, Slovenia, E-mail: parkseve@hotmail.com

Received: 01-Mar-2022; Manuscript No. AOT-22-59746; Editor assigned: 03-Mar-2022, PreQc No. AOT-22-59746(PQ); Reviewed: 07-Mar-2022, QC No. AOT-22-59746; Revised: 21-Mar-2022, Manuscript No. AOT-22-59746(R); Published: 04-Apr-2022, DOI: 10.4172/aot.1000178.

Citation: Stevens PY (2022) Recent Advanced Studies on Breast Cancer. J Oncol Res Treat 7: 178.

Copyright: © 2022 Stevens PY. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Description

The breast is made up of different tissues, ranging from very adipose tissue to very dense tissue. Inside this tissue is a network of lobes. Each lobe is made up of small, tube-like structures called lobules that contain mammary glands. Small vessels connect glands, lobules and lobes, carrying milk from the lobes to the nipple. The nipple is in the middle of the areola, which is darker around the nipple. Blood and lymphatic vessels also flow throughout the breast. Nourishes the blood cells. The lymphatic system drains the body of waste products. Lymphatic vessels connect to lymph nodes, which are little bean-shaped organs that aid in infection prevention. Lymph nodes are found in clusters throughout the body, including the neck, groin, and abdomen. The regional lymph nodes of the breast are located near the breast, like the lymph nodes under the arm. However, recent progress has been made in breast cancer, which we discuss here to find out in depth.

Advanced breast cancer with Ribociclib

The Addition of cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to letrozole has been shown to improve progression-free survival in patients with previously reported hormone receptor (HR)-positive, HER2-negative, treatment-innocent, Advanced breast cancer. Now, with a 6.6-year follow-up, overall survival improved with the inclusion of ribociclib (median 64 vs. 51 months) [1]. The continue to propose combining a CDK4/6 inhibitor with an aromatase inhibitor as a first-line treatment for many patients with HR-positive, HER2-negative, and metastatic breast cancer, as well as for ovarian suppression in patients with premenopausal depression. The probability of late recurrence of breast cancer in survivors is likely to rise as a result of these studies. In a reconsideration study, of the approximately 20,000 patients who survived 10 years after diagnosis, 9% were cumulative recurrences late 15 years after initial diagnosis and 15 percent after 25 years [2]. An increased risk of recurrence is linked to a high lymph node load, a big tumour size, and oestrogen receptor positivity. These data support the use of prolonged adjuvant endocrine therapy in hormone receptor-positive breast cancer patients.

Carboplatin in neoadjuvant therapy for triple negative breast cancer

The impact of including carboplatin in the neoadjuvant chemotherapy for Triple Negative Breast Cancer (TNBC) is being studied. The addition of carboplatin to anthracycline-based treatment raised the breast pathology to a complete response rate of 46% to 60% in a randomized trial, but did not improve five-year event-free survival or overall survival in patients with stage II to III TNBC [3]. The Study, however, lacked the power to predict survival outcomes.

Pembrolizumab was added to a carboplatin-containing chemotherapy treatment in a different trial, which increased event-free survival (overall survival outcomes were immature). Based on these findings, we recommend a combination of pembrolizumab and carboplatin for patients with stage II or III TNBC.

Breast cancer patients of cardio metabolic risk factors

Breast cancer treatments can affect a person's cardiovascular risk factors. In a study of approximately 15,000 newly diagnosed women with breast cancer and 75,000 corresponding controls, hypertension (10.9% vs. 8.9%) and diabetes were shown to persist two years after diagnosis (10.9% vs. 8.9%) (2.1% vs. 1.7%) 10 years (9.3% vs. 8.8%) [4]. As part of general surveillance, these results may be biased in the fact that breast cancer survivors are more likely to be found in the health care system. We recommend regular screening for cardio metabolic problems in the primary care setting for breast cancer survivors.

Pembrolizumab in PD-L1-positive TNBC

A randomized trial in patients with advanced Triple-Negative Breast Cancer (TNBC) previously improved the modest Progression-Free Survival (PFS) due to the addition of pembrolizumab to chemotherapy. Now, in preliminary reporting, pembrolizumab improved Overall Survival (OS) in the subgroup with tumors expressing cell death ligand 1 (PD-L1) programmed with a combined positive score (CPS) ≥ 10 (23 vs. 16 months) [5]. The OS in the PD-L1-positive CPS ≥ 1 subgroup showed a similar trend and PFS advantages. Based on these results, we added a prophylactic checkpoint inhibitor with chemotherapy to patients with PD-L1-positive TNBC.

Aromatase inhibitors against tamoxifen in premenopausal patients on adjuvant ovarian suppression for breast cancer

In premenopausal women with positive breast cancer, ovarian function suppression (OFS) is frequently added to adjuvant endocrine therapy, while it is uncertain whether it should be used with tamoxifen and the Aromatase Inhibitor (AI). AI enhanced the 10-year recurrence rate vs. tamoxifen (18% vs. 15%, Relative Risk [RR] 0.79) in a meta-analysis of four randomized studies involving 7000 premenopausal patients with HR-positive breast cancer receiving adjuvant OFS [6]. Although mortality rates for breast cancer were similar, distant recurrence rates improved (RR 0.83). Although tamoxifen is a viable alternative for premenopausal individuals getting aided OFS for HR-positive breast cancer, we prefer AI.

Assessing response to neoadjuvant therapy in breast cancer

Surrogates for survival outcomes in patients with breast cancer receiving Neoadjuvant Chemotherapy (NACT), such as pathological Complete Response (pCR) rates and Residual Cancer Burden (RCB), are being investigated in studies. Another meta-analysis of 54 neoadjuvant treatment studies including over 32,000 breast cancer patients [7] found that pCR was not a good surrogate for disease-free survival (DFS) or Overall Survival (OS) [7]. A separate study discovered a link between RCB and event-free survival. While we continue to use pCR to guide adjuvant therapy decisions in NACT patients, RCB adds to the prognostic information [8].

IV placement, venipuncture, and blood pressure measurements after breast cancer surgery

The only preventative measure proven to reduce the risk of lymphedema is the prevention of lymphadenopathy after breast cancer surgery; however, many patients are advised to avoid intravenous catheters, venipuncture and blood pressure measurements ipsilateral for the rest of their lives prior to surgery. The Society for Ambulatory Anesthesia, in collaboration with the American Society of Breast Surgeons, has released a statement indicating that, while they have axillary lymph node dissection, these procedures are not contraindicated in patients without lymphedema [9]. This statement is usually consistent with our policy. They encourage collaborative decision-making that considers the individual's risk factors, clinical condition and monitoring requirements, as well as patient preferences for lymphedema development.

Pregnancy after breast cancer

The effect of pregnancy on the rate of cancer recurrence in patients who have had breast cancer is unknown. A systematic assessment of 112,000 individuals with breast cancer found that those who had a subsequent pregnancy had higher disease-free survival and overall survival results than those who did not. The results are likely to be influenced by residual confusion, even though these findings are confirmed and continued in the adjusted models. We recommend waiting until the risk of recurrence is low and for teratogenicity

therapy to be completed before conceiving in patients who have had breast cancer.

References

1. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, et al. (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. *N Engl J Med* 386: 942-950.
2. Pedersen RN, Esen Bo, Mellekjær L, Christiansen P, Ejlersen B, et al. (2022) The Incidence of breast cancer recurrence 10-32 years after primary diagnosis. *J Natl Cancer Inst* 114: 391.
3. Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, et al. (2022) CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. *J Clin Oncol* JCO2101506.
4. Kwan ML, Cheng RK, Iribarren C (2022) Risk of cardiometabolic risk factors in women with and without a history of breast cancer: The Pathways heart study. *J Clin Oncol* JCO2101738.
5. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-Ah, et al. (2020) Final results of KEYNOTE-355: randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. *SABCS 2021*; GS1-02.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2022) Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A Patient-level meta-analysis of 7030 women from four randomised trials. *Lancet Oncol* 23: 382-392.
7. Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, et al. (2021) Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomized clinical trials of early stage breast cancer: Systematic review and meta-analysis. *BMJ* 375: e066381.
8. Yau C, Osdoit M, van der Noordaa M, et al. (2022) Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A Multi-center pooled analysis of 5161 patients. *Lancet Oncol* 23: 149-160.
9. Society for Ambulatory Anesthesia (SAMBA) (2021) Statement on intravenous catheter placement, venipuncture and blood pressure measurements in the ipsilateral upper extremity after breast cancer surgery with and without axillary lymph node dissection.